The Form 4 filing, an SEC report of insider stock trades, was filed on November 9, 2026. It covers sales made on November 6, 2026. Martine A. Rothblatt is chairperson and CEO of United Therapeutics (UTHR).
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-06 |
| Date of Latest Transaction | 2026-11-06 |
| Buy/Sell | sell |
| Transaction Count | 9 |
| Shares Transacted | 9,500 |
| Price | $564.51 |
| Total Transaction Value | $5,362,824.05 |
| Insider | |
| Ticker Symbol | UTHR |
| Company | UNITED THERAPEUTICS Corp |
| Insider Name | ROTHBLATT MARTINE A |
| Insider Title | Chairperson & CEO |
| Sector - Industry | Other - Unclassified |
| Holdings | |
| Total Shares Owned After Transaction | 324,443 |
| Position Size Change | 2.84% |
| Filing | |
| Filing Date | 2026-11-09 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
These were stock sales, reported with SEC transaction code S. The filing information lists nine sale transactions within a single filing.
What was the average price of the transaction?
The average sale price was $564.51 per share, rounded to the nearest cent. This average covers the nine transactions. Individual sale prices were not available in the transaction details.
How did this transaction affect the insider's holdings?
The sales reduced the reported share balance by 9,500 shares, leaving 324,443 shares owned afterward. The shares sold made up 2.84% of the shares owned before the sales.
What's the total transaction value?
The total value was $5,362,824.05 for all nine transactions. That is the amount rounded to cents from the recorded total of $5,362,824.046.
Are there any special circumstances around this transaction?
The filing information indicates a Rule 10b5-1 trading plan. These plans set trading instructions in advance. Footnote text and details tying the plan to each sale were not available. It is therefore unclear which of the nine sales the plan covers. The plan's start date and trading schedule are also unknown.
For research purposes only; not investment advice.